178 related articles for article (PubMed ID: 23527320)
21. Pharmacological treatment options for severe hypertriglyceridemia and familial chylomicronemia syndrome.
Chaudhry R; Viljoen A; Wierzbicki AS
Expert Rev Clin Pharmacol; 2018 Jun; 11(6):589-598. PubMed ID: 29842811
[TBL] [Abstract][Full Text] [Related]
22. Immune Responses to AAV-Vectors, the Glybera Example from Bench to Bedside.
Ferreira V; Petry H; Salmon F
Front Immunol; 2014; 5():82. PubMed ID: 24624131
[TBL] [Abstract][Full Text] [Related]
23. Biochemical Analysis of the Lipoprotein Lipase Truncation Variant, LPL
Hayne CK; Lafferty MJ; Eglinger BJ; Kane JP; Neher SB
Biochemistry; 2017 Jan; 56(3):525-533. PubMed ID: 27984852
[TBL] [Abstract][Full Text] [Related]
24. Cell therapy could be a potential way to improve lipoprotein lipase deficiency.
Wu W; Yin Y; Zhong J; Peng Y; Li S; Zheng L; Cao H; Zhang J
Lipids Health Dis; 2017 Oct; 16(1):189. PubMed ID: 28969646
[TBL] [Abstract][Full Text] [Related]
25. AAV1-LPL(S447X) gene therapy reduces hypertriglyceridemia in apoE2 knock in mice.
Rip J; van Dijk KW; Sierts JA; Kastelein JJ; Twisk J; Kuivenhoven JA
Biochim Biophys Acta; 2006 Oct; 1761(10):1163-8. PubMed ID: 16990047
[TBL] [Abstract][Full Text] [Related]
26. Adeno-associated virus LPL(S447X) gene therapy in LDL receptor knockout mice.
Rip J; Sierts JA; Vaessen SF; Kastelein JJ; Twisk J; Kuivenhoven JA
Atherosclerosis; 2007 Sep; 194(1):55-61. PubMed ID: 17087965
[TBL] [Abstract][Full Text] [Related]
27. Familial Chylomicronemia Syndrome: A Clinical Guide For Endocrinologists.
Falko JM
Endocr Pract; 2018 Aug; 24(8):756-763. PubMed ID: 30183397
[TBL] [Abstract][Full Text] [Related]
28. Complete rescue of lipoprotein lipase-deficient mice by somatic gene transfer of the naturally occurring LPLS447X beneficial mutation.
Ross CJ; Liu G; Kuivenhoven JA; Twisk J; Rip J; van Dop W; Excoffon KJ; Lewis SM; Kastelein JJ; Hayden MR
Arterioscler Thromb Vasc Biol; 2005 Oct; 25(10):2143-50. PubMed ID: 16002740
[TBL] [Abstract][Full Text] [Related]
29. Gene therapy enters the pharma market: the short story of a long journey.
Büning H
EMBO Mol Med; 2013 Jan; 5(1):1-3. PubMed ID: 23283747
[No Abstract] [Full Text] [Related]
30. Spectrum of mutations of the LPL gene identified in Italy in patients with severe hypertriglyceridemia.
Rabacchi C; Pisciotta L; Cefalù AB; Noto D; Fresa R; Tarugi P; Averna M; Bertolini S; Calandra S
Atherosclerosis; 2015 Jul; 241(1):79-86. PubMed ID: 25966443
[TBL] [Abstract][Full Text] [Related]
31. Severe hypertriglyceridaemia and pancreatitis in a patient with lipoprotein lipase deficiency based on mutations in lipoprotein lipase (LPL) and apolipoprotein A5 (APOA5) genes.
Koopal C; Bemelmans R; Marais AD; Visseren FL
BMJ Case Rep; 2019 Apr; 12(4):. PubMed ID: 30948399
[TBL] [Abstract][Full Text] [Related]
32. Lipoprotein lipase: recent contributions from molecular biology.
Auwerx J; Leroy P; Schoonjans K
Crit Rev Clin Lab Sci; 1992; 29(3-4):243-68. PubMed ID: 1489519
[TBL] [Abstract][Full Text] [Related]
33. A novel substitution at the translation initiator codon (ATG-->ATC) of the lipoprotein lipase gene is mainly responsible for lipoprotein lipase deficiency in a patient with severe hypertriglyceridemia and recurrent pancreatitis.
Yu XH; Zhao TQ; Wang L; Liu ZP; Zhang CM; Chen R; Li L; Liu G; Hu WC
Biochem Biophys Res Commun; 2006 Mar; 341(1):82-7. PubMed ID: 16431216
[TBL] [Abstract][Full Text] [Related]
34. Familial lipoprotein lipase deficiency: a case of compound heterozygosity of a novel duplication (R44Kfs*4) and a common mutation (N291S) in the lipoprotein lipase gene.
Overgaard M; Brasen CL; Svaneby D; Feddersen S; Nybo M
Ann Clin Biochem; 2013 Jul; 50(Pt 4):374-9. PubMed ID: 23761384
[TBL] [Abstract][Full Text] [Related]
35. Type I hyperlipoproteinemia due to a novel loss of function mutation of lipoprotein lipase, Cys(239)-->Trp, associated with recurrent severe pancreatitis.
Hoffmann MM; Jacob S; Luft D; Schmülling RM; Rett K; März W; Häring HU; Matthaei S
J Clin Endocrinol Metab; 2000 Dec; 85(12):4795-8. PubMed ID: 11134145
[TBL] [Abstract][Full Text] [Related]
36. Long-term course of lipoprotein lipase (LPL) deficiency due to homozygous LPL(Arita) in a patient with recurrent pancreatitis, retained glucose tolerance, and atherosclerosis.
Kawashiri MA; Higashikata T; Mizuno M; Takata M; Katsuda S; Miwa K; Nozue T; Nohara A; Inazu A; Kobayashi J; Koizumi J; Mabuchi H
J Clin Endocrinol Metab; 2005 Dec; 90(12):6541-4. PubMed ID: 16174715
[TBL] [Abstract][Full Text] [Related]
37. Pathogenic classification of LPL gene variants reported to be associated with LPL deficiency.
Rodrigues R; Artieda M; Tejedor D; Martínez A; Konstantinova P; Petry H; Meyer C; Corzo D; Sundgreen C; Klor HU; Gouni-Berthold I; Westphal S; Steinhagen-Thiessen E; Julius U; Winkler K; Stroes E; Vogt A; Hardt P; Prophet H; Otte B; Nordestgaard BG; Deeb SS; Brunzell JD
J Clin Lipidol; 2016; 10(2):394-409. PubMed ID: 27055971
[TBL] [Abstract][Full Text] [Related]
38. Targeting APOC3 in the familial chylomicronemia syndrome.
Gaudet D; Brisson D; Tremblay K; Alexander VJ; Singleton W; Hughes SG; Geary RS; Baker BF; Graham MJ; Crooke RM; Witztum JL
N Engl J Med; 2014 Dec; 371(23):2200-6. PubMed ID: 25470695
[TBL] [Abstract][Full Text] [Related]
39. Gene therapy for genetic lipid disorders: lipoprotein lipase deficiency as a paradigm.
Rader DJ
Neth J Med; 2005 Jan; 63(1):2-3. PubMed ID: 15719845
[No Abstract] [Full Text] [Related]
40. Breaking the chains of lipoprotein lipase deficiency: A pediatric perspective on the efficacy and safety of Volanesorsen.
den Hollander B; Brands MM; Nijhuis IJM; Doude van Troostwijk LJAE; van Essen P; Hofsteenge GH; Koot BG; Müller AR; Tseng LA; Stroes ESG; van de Ven PM; Wiegman A; van Karnebeek CDM
Mol Genet Metab; 2024 May; 142(1):108347. PubMed ID: 38401382
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
